Prognostic Stage 2 Breast Cancer AJCC v8 Terminated Phase 1 Trials for Talimogene laherparepvec (DB13896)

Also known as: Prognostic Stage II Breast Cancer AJCC v8

IndicationStatusPhase
DBCOND0140767 (Prognostic Stage 2 Breast Cancer AJCC v8)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04185311Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deletedTreatment